Genmab A/S (GMAB) Opens U.S. Hub in New Jersey to Drive Global Growth
Genmab A/S (NASDAQ:GMAB), a Danish biotech company founded in 1999, specializes in antibody-based therapies for cancer and serious diseases. Known for its technologies like HuMab-Mouse and UniBody, the corporation has historically partnered with major pharmaceutical companies such as Johnson & Johnson and AbbVie to bring its innovations to market. However, the company is now undergoing a strategic transformation to become a fully integrated global commercial entity.
In June 2025, Genmab A/S (NASDAQ:GMAB) opened a major new U.S. site in Plainsboro, New Jersey, signaling a shift from a partnership-driven model to direct commercialization of its therapies. This move gives the company greater control over its innovation, regulatory processes, and patient outreach, aligning with a broader biotech industry trend toward independence and vertical integration.
The business's oncology portfolio continues to gain traction. Tivdak (cervical cancer) received full FDA approval in April 2024, while Epkinly (lymphoma), which earned accelerated approval in 2023, has shown strong sales growth in the U.S. Genmab A/S (NASDAQ:GMAB)'s pipeline also remains active, with ongoing development of therapies like Epcoritamab and Acasunlimab. At the June 2025 ASCO meeting, the company presented promising Rina-S data, supporting an upcoming Phase III trial.
A healthcare professional wearing a health communications device discussing patient data with a colleague.
The corporation continues to benefit from its successful collaboration with Johnson & Johnson on DARZALEX, which remains a significant revenue driver. The company is also focused on long-term growth by investing in talent retention through stock-based incentives.
While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
3 minutes ago
- CNN
HHS further constrains certain vaccine advisers to the CDC, limiting their input in evidence reviews
Vaccines Federal agenciesFacebookTweetLink Follow In a further jolt to the process of reviewing and recommending vaccines at the US Centers for Disease Control and Prevention, another group of outside advisers to the agency was abruptly sidelined this week. In an email sent late Thursday evening, which was obtained by CNN, members of roughly 30 medical and public health organizations who serve as liaison members of the CDC's Advisory Committee on Immunization Practices, or ACIP, were told they could no longer participate in the committee's crucial workgroups. Liaison members don't vote at ACIP's public meetings on vaccine recommendations, but they can participate by asking questions and commenting on presentations. Behind the scenes, they have also historically done important work undertaking detailed evidence reviews of the safety and effectiveness of vaccines that helps to inform the group's votes. Those reviews happen in subcommittees called workgroups. As of late last year, ACIP had 11 active workgroups. In addition to studying scientific research, workgroups consider issues of public health importance like what age groups might get the most benefit from a vaccine, what an immunization costs and whether it will be accessible to people who should get it. Workgroups also help craft the language of the recommendations that are voted on by the full committee. Votes are typically held during ACIP's three public meetings each year. If ACIP approves a recommendation, it's forwarded to the CDC director for consideration. The director isn't bound by the committee's recommendation but usually follows it. Liaisons include groups like the American Medical Association, the American Academy of Pediatrics and the American Pharmacists Association. Members also represent nurses and public health officials, typically groups that play a significant role in delivering vaccinations. The latest move comes more than a month after US Health and Human Services Secretary Robert F. Kennedy Jr. removed all 17 voting members of ACIP, replacing them days later with eight of his own picks, many of whom have cast doubt on the safety of vaccines and public policy around vaccination. One member later dropped out during the required financial review. The email sent Thursday called the liaison members 'special interest groups' that are 'expected to have a 'bias' based on their constituency and/or population they represent.' 'It is important that the ACIP workgroup activities remain free of any influence from any special interest groups so ACIP workgroups will no longer include Liaison organizations,' the email said. Andrew Nixon, director of communications for HHS, said in a statement Friday that 'Under the old ACIP, outside pressure to align with vaccine orthodoxy limited asking the hard questions. The old ACIP members were plagued by conflicts of interest, influence and bias. We are fulfilling our promise to the American people to never again allow those conflicts to taint vaccine recommendations.' Dr. William Schaffner, an infectious disease expert at Vanderbilt University who has been participating in ACIP for 40 years as both a voting member and a liaison member, said the move to exclude professional organizations from the process of making vaccine recommendations was shortsighted. 'The organizations have a certain ownership in the recommendations because they participate,' Schaffner said. That participation increases buy-in from different stakeholder groups, which helps ACIP recommendations become the accepted standards of medical practice. Without that participation, Schaffner said, there's a risk that groups will make their own vaccine recommendations, which could lead to conflicting and confusing advice. In fact, some outside organizations, including the Vaccine Integrity Project, have already started the process of making independent vaccination recommendations. Shaffner said he also takes issue with the idea that liaison representatives are biased, which he says implies a conflict of interest. 'Every work group member, no matter who they are, is vetted for a conflict of interest,' he said, and that vetting process has only become more stringent over time as society has become more attuned to the problem. 'I have to turn down opportunities because they would interfere with my being on a work group, and that's something I do, or did,' he said. ACIP's charter spells out that some 30 specific groups should hold non-voting seats on the committee. It also allows the HHS secretary to appoint other liaison members as necessary to carry out the functions of the committee. On Friday, eight organizations that are liaisons to the committee said in a joint statement that they were 'deeply disappointed' and 'alarmed' to be barred from reviewing scientific data and informing the development of vaccine recommendations. 'To remove our deep medical expertise from this vital and once transparent process is irresponsible, dangerous to our nation's health, and will further undermine public and clinician trust in vaccines,' said the statement, which was sent by the American Medical Association. New outside experts may be invited to participate in the workgroups as needed based on their expertise, according to an HHS official who spoke on the condition that they not be named because they had not been authorized to share the information, but such inclusion will no longer be based on organizational affiliation. 'Many of these groups don't like us,' the official said. 'They've publicly attacked us.'
Yahoo
30 minutes ago
- Yahoo
Tech manufacturing has powered Asia - now it's a casualty of Trump's tariffs
When he began his trade war, President Donald Trump said his goal was to bring American jobs and manufacturing back to the US, reduce trade deficits and create a more level playing field for American companies competing globally. But after months of negotiations and many countries' refusal to meet America's demands, his strategy has taken a more punitive turn. US companies have been here before. Under Trump's first administration, when he imposed tariffs on Chinese exports, they scrambled to limit their exposure to Beijing, with many shifting production to Vietnam, Thailand and India to avoid higher levies. But his battery of new tariffs does not spare any of these economies. Stocks saw a sell-off, with benchmark indexes in Taiwan and South Korea in the red on Friday. Both countries are central to Asia's sprawling electronics production. The details are still hazy, but US firms from Apple to Nvidia will likely be paying more for their supply chains - they source critical components from several Asian countries and assemble devices in the region. Now they are on the hook - for iPhones, chips, batteries, and scores of other tiny components that power modern lives. It's not good news for Asian economies that have grown and become richer because of exports and foreign investment - from Japanese cars to South Korean electronics to Taiwanese chips. Soaring demand for all these goods fuelled trade surpluses with Washington over the years - and has driven President Trump's charge that Asian manufacturing has been taking American jobs away. In May, Trump told Apple CEO Tim Cook: "We put up with all the plants you built in China for years... we are not interested in you building in India, India can take care of themselves." Apple earns roughly half its revenue by selling iPhones that are manufactured in China, Vietnam and India. The tech giant reported bumper earnings for the three months to June, hours before Trump's tariff announcement on Thursday night, but now the future looks more uncertain. Chief executive Tim Cook told analysts on a conference call that tariffs had already cost Apple $800m (£600m) in the previous quarter, and may add $1.1bn in costs to the next quarter. Tech companies typically plan years ahead, but Trump's unpredictable tariff policy has paralysed businesses. Amazon's online marketplace, for instance, is just as dependent on China for what it sells in the US. But it's not yet clear what rates Chinese imports into the US could face because Beijing has yet to strike a deal with Washington - it has until 12 August to do so. Before they agreed to de-escalate, the two sides imposed tit-for-tat tariffs that reached a staggering 145% on some goods. But it's no longer just about China. On Thursday, Mr Cook said that most iPhones sold in the US now come from India. But Trump has just levelled a 25% tariff on Indian imports, after Delhi was unable to clinch a deal in time. Other firms chose to re-route their goods bound for the US through Vietnam and Thailand after the tariffs in Trump's first term. It became so common that it was called the "China+1" strategy. But this time, these trans-shipped goods are also being targeted. In fact, trans-shipping has been a big part of the US negotiations with Asian countries. Vietnamese imports face a 20% US levy but trans-shipped goods face 40%, according to Trump. It's harder still for advanced manufacturing like semiconductors - more than half of the world's chips, and most of its advanced ones, come from Taiwan. It is now subject to a 20% tariff. Chips are the backbone of Taiwan's economy, but also central to US efforts to gain a technological lead over China. So it is another US company, Nvidia, that will pay steep levies to put advanced chips by Taiwan's TSMC inside its AI products. But perhaps the biggest casualty of Trump's tariffs could well be Asia's e-commerce giants - as well as the American companies that rely on Chinese sellers and marketplaces. In a surprise move this week, Trump ditched the "de minimis" rule which exempted parcels under $800 from customs duties. He first did this in May, targeting such parcels from China and Hong Kong - and this was a blow for retailers like Shein and Temu, whose huge success has come from online sales in the West. Now American sites like eBay and Etsy have also lost that exemption - and the price of second-hand, vintage and handmade items for US customers will go up. President Trump says he is batting for Americans with these tariffs, but in a deeply globalised world, US firms and customers could also become casualties. There is still so much uncertainty that it is hard to see who the winners really are. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Stunning revisions show US added 258K fewer jobs than first reported
The U.S. added 258,000 fewer jobs in May and June than the Labor Department first reported, according to federal data released Friday. The Bureau of Labor Statistics (BLS) issued stunning revisions to its reports on May and June employment growth in an overall dismal July jobs report, drastically changing the picture of the U.S. economy. The U.S. only added 19,000 jobs in May compared to an initial report of 144,000, and only 14,000 in June after an initial report of 147,000, according to the BLS. Those two paltry totals, plus a July jobs gain of 73,000, means the U.S. added just 106,000 jobs over the past three months. 'Hiring has hit a wall in the U.S. Substantial downward revisions in payrolls means that private sector hiring has averaged a little more than 50,000 jobs over the past three months,' Bankrate senior economic analyst Mark Hamrick wrote in an analysis. While the BLS often revises job figures, the scale of the revisions — and what they said about the economy — stunned experts and investors after a week of relatively solid economic data. The July jobs report showed the labor market stalling out last month, with most industries other than health care reporting meager job gains or outright losses. The report comes two days after the Federal Reserve kept interest rates steady, but with two members of the Fed board calling for lower rates. President Trump raged against the Fed and its chair, Jerome Powell, in the hours before the report was released. Trump urged the Fed board to overrule Powell on future decisions and warned of future dissents from board members. The combination of slowing job gains and rising inflation, however, make it harder for the Fed to respond without exacerbating either issue. Cutting interest rates can fuel economic activity to support job growth, but also risks fueling inflation. Keeping interest rates at moderately high levels can help snuff out inflation, but could hold back the job market. 'Persistent policy uncertainty, tariffs, and diminished immigration flows paralyzing employers, the US economy is now flirting with job losses, revealing a labor market that is much weaker than most Fed policymakers had believed,' EY-Parthenon chief economist Gregory Daco wrote in an analysis. This dynamic, he said, now puts the Fed 'behind the curve.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
